Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)

NCT05262556 is registered in ClinicalTrials.gov with Amr Mohamed MD as lead sponsor.

NCT NCT05262556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)
Lead sponsor
Amr Mohamed MD
Phase
Phase 1
Overall status
Completed
Start date
December 15, 2022
Completion date
October 27, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine neoplasm, gastroenteropancreatic neuroendocrine tumor, mixed neuroendocrine-non neuroendocrine neoplasm, neuroendocrine carcinoma